Literature DB >> 30557657

MALDI-TOF MS for rapid diagnosis of Anaerobiospirillum succiniciproducens, an unusual causative agent of bacteraemia in humans. Two case reports and literature review.

Marina Alguacil-Guillen1, Luis Ramos-Ruperto2, Juan Carlos Ramos Ramos3, Angel Robles-Marhuenda2, Julio García-Rodriguez4, Jesús Mingorance4, María Pilar Romero-Gómez4.   

Abstract

Anaerobiospirillum succiniciproducens is a gram-negative anaerobic spiral rod which is part of the normal flora of dogs and cats and can produce bacteraemia and diarrhoea in humans. In this report we describe two cases of bacteraemia caused by A. succiniciproducens which was successfully identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). We present a comprehensive literature review of 48 cases of A. succiniciproducens bacteraemia in which we describe previous underlying conditions, clinical presentations, identification methodology and antibiotic susceptibility data.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaerobiospirillum succiniciproducens; Bacteraemia; MALDI-TOF

Mesh:

Year:  2018        PMID: 30557657     DOI: 10.1016/j.anaerobe.2018.12.003

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  3 in total

1.  Microbial Identification in the Clinical Microbiology Laboratory Using MALDI-TOF-MS.

Authors:  Iván Bloise; M Teresa Corcuera; Julio García-Rodríguez; Jesús Mingorance
Journal:  Methods Mol Biol       Date:  2022

2.  Bloodstream infection due to Herbaspirillum sp.: case series and review of literature.

Authors:  I Bloise; G V Guedez-López; M Tejedor-Rodríguez; M P Romero-Gómez; J García-Rodríguez; J Mingorance; E Cendejas-Bueno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-21       Impact factor: 3.267

3.  Jiedu-Yizhi Formula Alleviates Neuroinflammation in AD Rats by Modulating the Gut Microbiota.

Authors:  Jiale Wang; Xiaoting Zhu; Yuhui Li; Wenping Guo; Mingquan Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-31       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.